This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): melagatran/ximelagatran
Description: Exanta (ximelagatran) is an oral direct thrombin inhibitor. The mechanism of action of Exanta is to inhibit the activity of a clot-forming enzyme called thrombin, which is critical to the final step in the formation of blood clots.
Pink Sheet Exanta NDA dropped due to liver injury
Additional information available to subscribers only: